Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

Acrivon Therapeutics, Inc

Contributing Author

Recent Articles by Acrivon Therapeutics, Inc

Sep-02
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference ACRV GlobeNewswire
Aug-31
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer ACRV GlobeNewswire
Aug-12
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACRV ACRV +7.56% GlobeNewswire
Aug-05
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study ACRV +5.13% GlobeNewswire
Jul-21
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference ACRV GlobeNewswire
May-21
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit ACRV GlobeNewswire
May-15
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ACRV -7.81% ACRV -6.78% GlobeNewswire
May-13
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts ACRV GlobeNewswire
Apr-17
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities ACRV +6.59% GlobeNewswire
Apr-15
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ACRV GlobeNewswire
Mar-19
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights ACRV GlobeNewswire
Mar-17
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors ACRV GlobeNewswire
Feb-24
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference ACRV GlobeNewswire
Feb-23
Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress ACRV GlobeNewswire
Feb-18
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory ACRV GlobeNewswire
Jan-23
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress ACRV GlobeNewswire
Jan-08
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 ACRV -34.58% GlobeNewswire
Jan-06
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast ACRV +31.44% GlobeNewswire
Dec-17
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast ACRV GlobeNewswire
Dec-17
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates ACRV GlobeNewswire
Nov-13
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights ACRV -9.21% ACRV +8.21% GlobeNewswire
Oct-22
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference ACRV GlobeNewswire
Oct-01
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ACRV GlobeNewswire
Aug-13
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights ACRV ACRV +6.11% GlobeNewswire
May-14
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights ACRV GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)